文献速递白血病

尼洛替尼联合聚乙二醇干扰素α-2a一线治疗慢性期慢性髓性白血病的PETALs试验最终结果

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.
PubMed 文献 · Lancet Haematol · 2026-01-01

PETALs是一项开放标签、多中心、随机3期试验,纳入200例新诊断慢性期慢性髓性白血病患者,比较尼洛替尼单药与尼洛替尼联合聚乙二醇干扰素α-2a的疗效与安全性。主要终点12个月MR4·5累积率在联合组显著更高(24% vs 15%,p=0·048),但联合组精神类3-4级事件较多。

要点

  • 尼洛替尼联合Peg-IFN较单药提高12个月MR4·5率(24% vs 15%,p=0·048)。
  • 两组3-4级血液学副作用相当(14 vs 14),以无出血的血小板减少为主。
  • 联合组精神类3-4级事件6例(含3例自杀未遂),需警惕并及时停药。

核心结论

  • 在新诊断CP-CML中,尼洛替尼联合Peg-IFN较TKI单药诱导更高的初始MR4·5率,但附加副作用。

研究设计与样本

  • 开放标签、多中心、随机3期试验,自27家法国学术机构入组新诊断CP-CML患者。
  • 按1:1随机分配至尼洛替尼300mg每日两次单药组或联合皮下Peg-IFN组(首月30μg/周,此后45μg/周,最长2年)。
  • 按Sokal指数和EUTOS长期生存指数分层,主要终点为意向治疗人群(n=200)的MR4·5累积率。

主要发现

  • 2014年8月6日至2016年9月29日入组205例,排除5例不合格后200例随机分配(尼洛替尼组99例,联合组101例)。
  • 中位年龄45岁(IQR 36-55),男性130例(65%),女性70例(35%),中位随访67个月(IQR 32·6-70·6)。
  • 12个月MR4·5率联合组24%(95%CI 16·0-34·1)vs 尼洛替尼组15%(8·6-24·2),p=0·048。
  • 3-4级血液学副作用两组均为14例,以3-4级无出血血小板减少为主(联合组6例 vs 尼洛替尼组5例)。
  • 联合组精神类3-4级事件6例(6%,含3例自杀未遂),尼洛替尼组5例(5%,含1例自杀未遂)。

关键数值与推荐

  • MR4·5定义为BCR::ABL1国际标准(IS)≤0·0032%。
  • 联合组12个月MR4·5累积率24%(95%CI 16·0-34·1),尼洛替尼组15%(95%CI 8·6-24·2),p=0·048。

临床怎么用

  • 尼洛替尼联合Peg-IFN可作为提高早期深度分子学反应的治疗选择,但需权衡附加副作用。
  • 出现精神类事件时应立即停用Peg-IFN并寻求精神科建议。

局限性

  • 早期分子学反应能否转化为持续无治疗生存尚需足够把握度的随机试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Second generation tyrosine kinase inhibitors (TKIs) have improved response rates in patients with chronic phase chronic myeloid leukaemia (CP-CML). Phase 2 trials demonstrated increased deep molecular response rates when combining second generation TKIs with pegylated interferon alfa (Peg-IFN). This trial aimed to evaluate the efficacy and the safety of combining nilotinib with Peg-IFN alfa-2a in patients with newly diagnosed CP-CML. METHODS: In PETALs, this open-label, randomised, multicentre phase 3 trial, we enrolled patients with newly diagnosed CP-CML from 27 French academic institutions via a centrally-generated electronic system in a 1:1 ratio to two groups: 300 mg oral nilotinib alone twice a day (the nilotinib only group) or 300 mg nilotinib twice a day combined with subcutaneous Peg-IFN (30 μg per week for the first month of treatment and 45 μg per week thereafter) for a maximum of 2 years. The randomly allocated patients were stratified by their Sokal index and European Treatment and Outcome Study long-term survival index. Eligible patients had major BCR::ABL1 transcripts, an Eastern Cooperative Oncology Group performance score of two or lower, who had never received TKIs, and were aged between 18 and 65 years. The primary endpoint was the cumulative rate of molecular response 4·5 (MR4·5; defined as BCR::ABL1 international scale [IS] of 0·0032% and lower), analysed in the intention-to-treat population (n=200). This trial is registered at ClinicalTrials.gov, NCT02201459, and is completed. FINDINGS: 205 patients were enrolled between Aug 6, 2014, and Sept 29, 2016, after which five patients were declared ineligible and excluded, resulting in 200 patients being randomly allocated (99 to the nilotinib group and 101 to the combination group). The median age at diagnosis was 45 years (IQR 36-55); 130 patients (65%) were male and 70 (35%) were female. Median follow-up in this cohort was 67 months (IQR 32·6-70·6). The primary objective was met, with higher rates of MR4·5 in the combination group (24% [95% CI 16·0-34·1] vs 15% [8·6-24·2], p=0·048) at month 12. There were equivalent grade 3-4 haematological side effects in the both groups (14 vs 14) with a predominance for grade 3-4 thrombocytopenia without haemorrhages (six in the combination group vs five in the nilotinib group). Psychiatric grade 3-4 events occurred in six (6%) patients in the combination group (including three unsuccessful suicide attempts) compared with five (5%) in the nilotinib group (including one unsuccessful suicide attempt). Six vascular events also occurred in six patients in the combination group and seven vascular events in five patients in the nilotinib group (all grades 3-4). INTERPRETATION: In this setting, Peg-IFN combined with nilotinib induced higher initial rates of MR4·5 compared to TKI monotherapy, despite additional side effects. The onset of psychiatric events might promote immediate cease of Peg-IFN and psychiatrist advice Whether this early molecular response translates into sustained treatment-free survival should be studied in a randomised trial sufficiently powered for this outcome. FUNDING: Novartis Pharma.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Nicolini FE, Etienne G, Huguet F, et al. Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial. Lancet Haematol. 2026. PMID: 42069411. doi:10.1016/S2352-3026(26)00043-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。